HealthTalker appoints Collie Turner
April 22, 2010Sales and Marketing Company news, HealthTalker, appointment, new hires, pharm marketing, sales and marketing
Collie Turner has joined US word-of-mouth marketing agency HealthTalker’s leadership team as senior director of strategic partnerships. She will focus on driving new …
Genzyme fined $175m for manufacturing problems
April 22, 2010Manufacturing and Production Cerezyme, Cerezyme Fabrazyme Gaucher's Genzyme, Fabrazyme, Gaucher's, Genzyme, manufacturing compliance
The FDA seems to have lost patience with biotechnology company Genzyme over contamination problems at its manufacturing facilities, levying a …
Elan looks again at hiving off drug delivery unit EDT
April 22, 2010Research and Development, Sales and Marketing Elan
Irish drugmaker Elan says it is once again considering spinning out its drug delivery division, Elan Drug Technology, after abandoning …
Bayer lures Novartis’ Reinhardt for top healthcare post
April 22, 2010Research and Development, Sales and Marketing Bayer, appointment, research and development, sales and marketing
German pharma company Bayer has ended its search for someone to replace healthcare chief executive Arthur Higgins, appointing Dr Jörg …
Novartis shines in first quarter
April 21, 2010Sales and Marketing 2010 financials, Alcon, Novartis
Novartis has had a very strong first quarter, its first under new chief executive Joe Jimenez, delivering a 25% increase …
Astellas eyes oncology growth
April 21, 2010Research and Development, Sales and Marketing Astellas, Astellas Pharma Europe
Astellas Pharma Europe has set its sights on the oncology market, earmarking the therapy area as its latest “franchise focus” …
Volcanic ash fallout hits pharma
April 21, 2010Manufacturing and Production Clinical Supply Operations, disaster, logistics, supply chain
The headline news in the wake of the Icelandic volcano eruption has been of stranded passengers struggling to get home …
Secondary endpoints failure take shine off Benlysta
April 21, 2010Sales and Marketing GSK, HGS, Lupus
GlaxoSmithKline’s lupus treatment has failed to reach a statistically significant secondary endpoint in the second of two phase III trials. …
Wyeth’s Ursula Franklin joins Red Kite
April 21, 2010Business Services, Sales and Marketing Red Kite, appointment, coaching, development, leadership, sales and marketing, strategic planning, strategy, training
Red Kite has appointed Ursula Franklin to head up its new Transformation division. She joins from Wyeth Europa, now part …
GSK’s Arzerra conditionally approved in Europe
April 20, 2010Research and Development, Sales and Marketing Arzerra, GSK, leukaemia
GlaxoSmithKline’s orphan cancer treatment Arzerra has been given conditional marketing authorisation in the European Union. Arzerra (ofatumumab) can be used …
Oracle buys eClinical specialist Phase Forward for $685m
April 20, 2010Research and Development Covance, Oracle, Phase Forward
Business software giant Oracle has taken a leap forward in the healthcare arena with a $685 million cash offer to …
Emerging markets and generics poised to drive pharma growth
April 20, 2010Sales and Marketing IMS, em, emerging markets
The global pharma market will reach $1.1 trillion in 2014 through growth primarily driven by emerging markets and generics, according …
Lilly faces substantial costs from US health reform
April 20, 2010Sales and Marketing 2010 financials, Obama, lilly
Lilly expects to lose up to $485 million this year as a direct result of the US healthcare reforms, but …
ABPI appoints Roche’s Paul Catchpole
April 20, 2010Sales and Marketing ABPI, UK, appointment, sales and marketing
UK industry association the ABPI has appointed Paul Catchpole as director of value and access. He will join the association …
Third Apotex plant cited in FDA warning letter
April 19, 2010Manufacturing and Production Apotex, generics, manufacturing compliance
Canada’s Apotex has been sent a warning letter citing manufacturing violations at a facility in Toronto that are identical to …
Trial boost for Merck KGaA’s cladribine
April 19, 2010Research and Development Cladribine, MS, Merck KGaA, Merck Serono
New data from German pharma company Merck suggests its oral multiple sclerosis treatment cladribine has been successful in treating relapsing …
Novartis set to boost generic portfolio
April 19, 2010Sales and Marketing Novartis, Sandoz, generics
Novartis’ generics arm Sandoz has signed a deal to acquire US-based inhalable drug specialist Oriel Therapeutics. Sandoz will gain rights …
MedImmune: building a biologics future
April 19, 2010Research and Development MedImmune, biologics
I paid my visit to MedImmune’s UK headquarters in Cambridge only days after its parent company AstraZeneca announced the closure …
Action Pharma appoints new chief executive
April 19, 2010Research and Development Action Pharma, appointment, research and development
Ingelise Saunders has joined Danish biotech Action Pharma as its new chief executive. She will be involved in seeking partners …
Lane Earl Cox wins allergy blood test account
April 16, 2010Medical Communications LEC, Phadia, allergy
Healthcare advertising agency Lane Earl & Cox has won the account to promote an allergy blood test product from diagnostics …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
